相似文献
1
FDG PET/CT demonstration of pancreatic metastasis from prostate cancer.
Clin Nucl Med. 2011 Oct;36(10):961-2. doi: 10.1097/RLU.0b013e3182291d1a.
2
(18)F-FDG-PET/CT findings in pancreatic metastasis.
Radiol Med. 2015 Oct;120(10):887-98. doi: 10.1007/s11547-014-0473-1. Epub 2015 Mar 22.
3
Comment on: "Tumor aggressiveness and patient outcome in cancer of the pancreas assessed by dynamic 18F-FDG PET/CT".
J Nucl Med. 2014 Feb;55(2):350-1. doi: 10.2967/jnumed.113.130138. Epub 2013 Dec 9.
4
Reply: Comment on: "Tumor aggressiveness and patient outcome in cancer of the pancreas assessed by dynamic 18F-FDG PET/CT".
J Nucl Med. 2014 Feb;55(2):351-2. doi: 10.2967/jnumed.113.132845. Epub 2013 Dec 9.
5
Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
J Gastroenterol Hepatol. 2013 Feb;28(2):255-61. doi: 10.1111/jgh.12068.
6
Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
Pancreas. 2013 Jan;42(1):11-9. doi: 10.1097/MPA.0b013e3182550d77.
7
Comparison of 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours.
Eur J Nucl Med Mol Imaging. 2012 May;39(5):846-51. doi: 10.1007/s00259-012-2061-8. Epub 2012 Jan 26.
8
Asymptomatic Solitary Metastasis to the Testis From Prostate Carcinoma Detected by FDG PET/CT.
Clin Nucl Med. 2016 Jan;41(1):86-7. doi: 10.1097/RLU.0000000000001004.
9
Usefulness of 18F-FDG PET/CT in an unusual case of solid-pseudopapillary pancreatic tumor in childhood with aggressive behavior.
Clin Nucl Med. 2013 Jan;38(1):e35-7. doi: 10.1097/RLU.0b013e31824c5e92.
10
The value of positron emission tomography/computed tomography for evaluating metastatic disease in patients with pancreatic cancer.
Pancreas. 2012 Aug;41(6):897-903. doi: 10.1097/MPA.0b013e318252f4f5.
引用本文的文献
1
Atypical Metastases from Prostate Cancer: Alpha-Methylacyl-Coenzyme A Racemase (AMACR) as a Potential Molecular Target in Prostate-Specific Membrane Antigen-Negative Prostate Adenocarcinoma.
Biomolecules. 2024 Dec 26;15(1):17. doi: 10.3390/biom15010017.
2
Malignant biliary obstruction due to metastatic non-hepato-pancreato-biliary cancer.
World J Gastroenterol. 2022 Mar 14;28(10):985-1008. doi: 10.3748/wjg.v28.i10.985.
3
(18)F-FDG-PET/CT findings in pancreatic metastasis.
Radiol Med. 2015 Oct;120(10):887-98. doi: 10.1007/s11547-014-0473-1. Epub 2015 Mar 22.
4
MR molecular imaging of prostate cancer with a peptide-targeted contrast agent in a mouse orthotopic prostate cancer model.
Pharm Res. 2012 Apr;29(4):953-60. doi: 10.1007/s11095-011-0635-y. Epub 2011 Dec 3.
本文引用的文献
1
C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy.
Clin Nucl Med. 2011 Mar;36(3):192-8. doi: 10.1097/RLU.0b013e318208f140.
2
An interesting contamination artifact appearing in I-(131) whole-body imaging after ablative therapy.
Rev Esp Med Nucl. 2011 Jan-Feb;30(1):36-7. doi: 10.1016/j.remn.2010.07.003. Epub 2011 Jan 5.
3
Pancreatic metastasis from prostate cancer.
Case Rep Med. 2010;2010:826273. doi: 10.1155/2010/826273. Epub 2010 May 23.
4
Synchronous prostate cancer incidentally detected by FDG-PET/CT in staging a patient with newly diagnosed nasopharyngeal cancer.
Clin Nucl Med. 2009 Dec;34(12):962-3. doi: 10.1097/RLU.0b013e3181bed0ae.
5
Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET.
Nat Rev Urol. 2009 Jun;6(6):317-23. doi: 10.1038/nrurol.2009.81. Epub 2009 May 12.
6
Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients.
Hum Pathol. 2000 May;31(5):578-83. doi: 10.1053/hp.2000.6698.
7
Features of unusual metastases from prostate cancer.
Br J Radiol. 1999 Oct;72(862):933-41. doi: 10.1259/bjr.72.862.10673942.
8
Metastases to the pancreas.
Br J Radiol. 1998 Nov;71(851):1208-14. doi: 10.1259/bjr.71.851.10434919.
Zotero 插件